Lu et al. (2022) demonstrated that Isosaponarin could inhibit Ca2+‐dependent PKC/SNAP‐25 and MARCKS pathways in synaptosomes, reducing the availability of synaptic vesicles and glutamate release, suggesting its potential as a therapeutic strategy for neurological disorders. This evidence concerns the gene PRRT2 and nervous system disorder.